Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
???displayArticle.abstract???
The serotonin (5-hydroxytryptamine, 5-HT) transporter (SERT) protein plays a central role in terminating 5-HT neurotransmission and is the most important therapeutic target for the treatment of major depression and anxiety disorders. We report an innovative, versatile, and target-selective quantum dot (QD) labeling approach for SERT in single Xenopus oocytes that can be adopted as a drug-screening platform. Our labeling approach employs a custom-made, QD-tagged indoleamine derivative ligand, IDT318, that is structurally similar to 5-HT and accesses the primary binding site with enhanced human SERT selectivity. Incubating QD-labeled oocytes with paroxetine (Paxil), a high-affinity SERT-specific inhibitor, showed a concentration- and time-dependent decrease in QD fluorescence, demonstrating the utility of our approach for the identification of SERT modulators. Furthermore, with the development of ligands aimed at other pharmacologically relevant targets, our approach may potentially form the basis for a multitarget drug discovery platform.
???displayArticle.pubmedLink???
21970724
???displayArticle.pmcLink???PMC3235909 ???displayArticle.link???J Am Chem Soc ???displayArticle.grants???[+]
Adkins,
Interactions of tryptamine derivatives with serotonin transporter species variants implicate transmembrane domain I in substrate recognition.
2001, Pubmed
Adkins,
Interactions of tryptamine derivatives with serotonin transporter species variants implicate transmembrane domain I in substrate recognition.
2001,
Pubmed
Akunne,
[3H] cocaine labels a binding site associated with the serotonin transporter in guinea pig brain: allosteric modulation by paroxetine.
1992,
Pubmed
Alivisatos,
The use of nanocrystals in biological detection.
2004,
Pubmed
Bentzen,
Surface modification to reduce nonspecific binding of quantum dots in live cell assays.
2005,
Pubmed
Carneiro,
Functional coding variation in recombinant inbred mouse lines reveals multiple serotonin transporter-associated phenotypes.
2009,
Pubmed
Chattopadhyay,
Quantum dot semiconductor nanocrystals for immunophenotyping by polychromatic flow cytometry.
2006,
Pubmed
Chen,
Characterization of an allosteric citalopram-binding site at the serotonin transporter.
2005,
Pubmed
Dolder,
Pharmacological and clinical profile of newer antidepressants: implications for the treatment of elderly patients.
2010,
Pubmed
Duric,
A negative regulator of MAP kinase causes depressive behavior.
2010,
Pubmed
Gao,
In vivo molecular and cellular imaging with quantum dots.
2005,
Pubmed
Gussin,
Binding of muscimol-conjugated quantum dots to GABAC receptors.
2006,
Pubmed
,
Xenbase
Henry,
Getting the message across: a recent transporter structure shows the way.
2006,
Pubmed
Henry,
Bound to be different: neurotransmitter transporters meet their bacterial cousins.
2007,
Pubmed
Kovtun,
Visualization of the cocaine-sensitive dopamine transporter with ligand-conjugated quantum dots.
2011,
Pubmed
Kroenke,
Similar effectiveness of paroxetine, fluoxetine, and sertraline in primary care: a randomized trial.
2001,
Pubmed
Medintz,
Quantum dot bioconjugates for imaging, labelling and sensing.
2005,
Pubmed
Millan,
Multi-target strategies for the improved treatment of depressive states: Conceptual foundations and neuronal substrates, drug discovery and therapeutic application.
2006,
Pubmed
Nestler,
Neurobiology of depression.
2002,
Pubmed
Ramamoorthy,
Phosphorylation and sequestration of serotonin transporters differentially modulated by psychostimulants.
1999,
Pubmed
Ramsey,
Serotonin transporter function and pharmacology are sensitive to expression level: evidence for an endogenous regulatory factor.
2002,
Pubmed
,
Xenbase
Rosenthal,
Targeting cell surface receptors with ligand-conjugated nanocrystals.
2002,
Pubmed
,
Xenbase
Rosenthal,
Biocompatible quantum dots for biological applications.
2011,
Pubmed
Starr,
SB-649915-B, a novel 5-HT1A/B autoreceptor antagonist and serotonin reuptake inhibitor, is anxiolytic and displays fast onset activity in the rat high light social interaction test.
2007,
Pubmed
Sánchez,
Escitalopram versus citalopram: the surprising role of the R-enantiomer.
2004,
Pubmed
Thompson,
Transgenic elimination of high-affinity antidepressant and cocaine sensitivity in the presynaptic serotonin transporter.
2011,
Pubmed
Tomlinson,
Biotin tethered homotryptamine derivatives: high affinity probes of the human serotonin transporter (hSERT).
2011,
Pubmed
,
Xenbase
Warnement,
Controlling the reactivity of ampiphilic quantum dots in biological assays through hydrophobic assembly of custom PEG derivatives.
2008,
Pubmed
Zhang,
An affinity-based fluorescence polarization assay for protein tyrosine phosphatases.
2007,
Pubmed
